Pricing Log in Create free account
Saturday 17 October 2026 Export SXTC’s income statement to Excel — free account

China SXT Pharmaceuticals, Inc.

SXTC Healthcare Drug Manufacturers Specialty & Generic

China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.

0.07 0.00 0.00%
Market cap
$710.0K
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
3/9
Altman Z
−0.84
Beneish M
−2.12
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 78.70%

Capital & Financial Ratios $m

Market Cap 0.71
Revenue 4.57
Net Income (16.68)
Free Cash Flow (9.37)
Net Debt (27.18)
Current Ratio 7.94 (at or above 1.5: strong)
Debt/Equity 0.03 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.02) (negative: loss-making)
P/S ratio 0.00
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (45.58%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −5.9×, against a ten-year median of −1.9×; over the ten years it ranged from −5.9× in 2026 to 0.0× in 2021.
EV/FCF against its own 10 years 50.45%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2016 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 17 12 18 28
Receivables 1 1 2 3
Inventory 1 1 1 1
Other 0 0 0 2
20 14 21 35
2023 2024 2025 2026
Payables 1 1 1 0
ST’ Debt 3 2 1 0
Other 0 0 0 0
14 9 6 4

Compound Annual Growth %

10y 5y 3y
Sales (11.17%) (24.94%) (16.74%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 44.61% 13.23% 26.45%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — 1
’25 — — — — 2
’24 — — — — 2
’23 — — — — 2
’22 — — — — 3
’21 — — — — 5
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (4)
’25 — — — — (2)
’24 — — — — (2)
’23 — — — — 0
’22 — — — — 0
’21 — — — — (1)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 — — — — —
’26 (4) — (2) — (4)
’25 (2) — (1) — (2)
’24 (2) — (1) — (2)
’23 0 — (1) — 0
’22 0 — 0 — 0
’21 (1) — 0 — (1)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 — — — — —
’26 — — — — (730.40)
’25 — — — — (27.70k)
’24 — — — — (341.01k)
’23 — — — — (2.13m)
’22 — — — — (5.52)
’21 — — — — (3.82)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low — — 780,000.00 266,400.00 151,500.00 27,000.00 19,812.00 3,600.00 3,732.00 0.06

Analyst estimates 2027–2029

Powerpack
High — — 28,020,000.00 1,776,000.00 1,536,000.00 684,000.00 204,000.00 40,440.00 68,376.00 83,760.00
People
People Employees — 105 96 97 96 87 78 75 75 56
Revenue/emp, $m 0.00 0.07 0.07 0.05 0.05 0.03 0.03 0.03 0.02 0.02
Income, $m
Income, $m Revenue 5 7 7 5 5 3 2 2 2 1
Gross margin, % 47.36 48.46 65.77 52.37 59.44 48.10 21.62 28.73 21.10 21.85
EBT 2 2 2 (10) (3) (5) (6) (3) (3) (6)
EBT margin, % 32.37 23.19 25.55 (201.26) (61.56) (207.81) (301.00) (160.67) (189.77) (545.22)
Net income 1 1 2 (10) (3) (6) (6) (3) (3) (6)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.24 0.35 0.34 0.84 6.64 2.50 0.00 0.00 17,409.00 133.89
Earnings 0.06 0.06 0.07 (1.66) (3.82) (5.52) (2,125,373.00) (341,014.90) (27,701.49) (730.40)
Cash flow 0.01 0.10 0.01 0.15 (1.83) 0.26 0.00 0.00 (23,453.00) (472.65)
Capex (0.01) (0.05) (0.03) (0.07) (0.13) (0.06) 0.00 0.00 635.00 0.00
Free cash flow 0.01 0.04 (0.02) 0.09 (1.96) 0.20 0.00 0.00 (22,818.00) (472.65)
Book value 0.09 0.16 0.54 1.52 22.18 15.79 0.00 0.00 154,398.00 3,494.99
Shares, m 20 20 21 6 1 1 0 0 0 0
Valuation, ×
Valuation, × P/E 143.50 143.50 101.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/B 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales 0.00 0.00 0.00 (0.05) (1.34) (1.83) (3.04) (2.11) (3.79) (5.94)
EV/FCF 0.00 0.00 (3.72) 0.18 3.73 6.79 16.41 2.93 2.80 2.90
Cash, $m
Cash, $m Operating cash flow 0 2 0 1 (1) 0 0 (2) (2) (4)
Capex 0 (1) (1) 0 0 0 0 0 0 —
Free cash flow 0 1 0 1 (1) 0 0 (2) (2) (4)
Balance, $m
Balance, $m Working capital 1 2 9 7 5 5 5 5 15 30
Total debt 0 0 0 7 0 2 3 2 1 1
Net debt 0 0 (9) (1) (13) (14) (14) (10) (17) (27)
Shareholders’ equity 2 3 11 9 16 16 15 14 15 30
Returns, %
Returns, % ROA 20.21 18.15 12.25 (52.53) (9.77) (16.85) (18.81) (11.76) (14.75) (22.00)
ROIC 47.93 33.86 58.66 (9.48) (51.90) (111.79) (453.09) (36.86) 0.00 (175.91)
ROE 91.32 46.22 21.39 (100.32) (21.67) (35.42) (38.15) (21.65) (22.50) (27.49)
Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jan 0001

Charts ten years each

China SXT Pharmaceuticals, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AKAN Akanda Corp. $3.5M — — — — −472.01% (below 0%: shrinking) (197.87%) 0.00% Compare
PRFX PainReform Ltd. $2.6M — (loss-making) — (loss-making) — n/m +52.56% (above 0%: growing) 0.00% 0.00% Compare
BTAIQ BioXcel Therapeutics, Inc. $2.3M — (loss-making) — (loss-making) +51.67% (above 0%: growing) n/m +51.51% (above 0%: growing) 87.91% (5,600.55%) Compare
IMCC IM Cannabis Corp. $2.2M — (loss-making) — (loss-making) −40.28% (below 0%: shrinking) n/m −266.81% (below 0%: shrinking) 19.83% (27.54%) Compare
NEPTF Neptune Wellness Solutions Inc. $1.6M — (loss-making) — (loss-making) −37.75% (below 0%: shrinking) n/m +53.44% (above 0%: growing) 13.62% (232.88%) Compare
PTPI Petros Pharmaceuticals, Inc. $1.0M — (loss-making) — (loss-making) +1,070.55% (above 0%: growing) n/m +71.27% (above 0%: growing) 73.82% 0.00% Compare
SBFM Sunshine Biopharma, Inc. $990.0K — (loss-making) — (loss-making) −1.56% (below 0%: shrinking) n/m +49.38% (above 0%: growing) 26.20% (17.41%) Compare
LSDIF Lucy Scientific Discovery Inc. $900.0K — (loss-making) — — n/m −493.98% (below 0%: shrinking) 59.79% (8,891.75%) Compare
SXTC China SXT Pharmaceuticals, Inc. $710.0K — (loss-making) — (loss-making) −16.76% (below 0%: shrinking) +92.67% (above 0%: growing) −107.59% (below 0%: shrinking) 44.09% 0.00%
Median of peers $1.9M — — −1.56% — +50.45% 23.02% (22.47%)

All 86 Drug Manufacturers Specialty & Generic stocks →

China SXT Pharmaceuticals, Inc. (SXTC) key facts

  • Concern: China SXT Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 million, down 34.6% from fiscal 2025.
  • China SXT Pharmaceuticals, Inc. (SXTC) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SXTC traded at $0.07, a market capitalization of $710,000.00.
  • Return on equity was −27.5% and debt-to-equity 0.03.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −0.84 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

China SXT Pharmaceuticals, Inc. (SXTC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SXTC · Data as of Jan 3, 0001 · For information only; not investment advice. · © 2026 stockrow.com